Poly-α, β-aspartyl-Arg-Gly-Asp-Phe: a novel polymeric nanomedicine. Issue 1 (28th October 2014)

• Record Type: Journal Article
• Authors: Chen, Shuangling; Wang, Yuji; Li, Shan; Wang, Yaonan; Zhao, Ming; Zhu, Haimei; Wu, Jianhui; Peng, Shiqi
• Is Part Of: MedChemComm. Volume 6:Issue 1(2015:Jan.)
• Page Start: 182
• Page End: 186
• Publication Date: 2014-10-28
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c4md00331d
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : High anti-thrombotic efficacy, action target and nano-structure of a novel nanomedicine were described. Abstract : Thrombosis is a pathological condition and has been one of the most prominent causes of morbidity and mortality. Poly-α, β-aspartic acid is a biodegradable polymer, and RGD-tetrapeptides target thrombus. These led to the design of poly-α, β-aspartyl-Arg-Gly-Asp-Phe (PD-RGDF) as a novel polymeric therapeutic drug. In the solid state and ultrapure water PD-RGDF formed nanoparticles of substantially identical diameter. In vitro the nanoparticles inhibited GPIIb/IIIa expression of activated platelets, thereby making the in vitro anti-platelet aggregation efficacy greatly increase. In vivo the anti-thrombotic efficacy of PD-RGDF was 500-fold higher than that of RGDF.